ストックスクリーナーアプリを入手
0.00
100.00%
-4.66
前日終値:
$4.66
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$1.05B
収益：
$81.04M
当期純損益:
$161.96M
株価収益率:
0.00
EPS:
0.7146
ネットキャッシュフロー:
$-144.00M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
0.00 | 1.05B | 81.04M | 161.96M | -144.00M | 0.7146 |
VRTX
Vertex Pharmaceuticals Inc
|
438.36 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.39 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.71 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.91 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.26 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 開始されました | SVB Securities | Outperform |
| 2023-01-19 | アップグレード | UBS | Neutral → Buy |
| 2023-01-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-01-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-06-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Underperform |
| 2021-04-26 | 開始されました | Guggenheim | Neutral |
| 2020-12-10 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-09-08 | 開始されました | Credit Suisse | Neutral |
| 2020-09-08 | 開始されました | Jefferies | Hold |
すべてを表示
Curevac N V (CVAC) 最新ニュース
Health News Roundup: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology; AstraZeneca's China boss says drugmaker will seek to "love the Communist Party" and more - Devdiscourse
CureVac NV stock (NL0015436031): merger integration and mRNA update - AD HOC NEWS
CureVac NV stock (NL0015436031): mRNA pioneer restructures and eyes next vaccine chapter - AD HOC NEWS
CureVac stock (NL0015436031): FDA clears deal path with GSK after BioNTech settlement - AD HOC NEWS
CureVac N.V.Ordinary Shares (NQ: CVAC - FinancialContent
TradingKey - TradingKey
CureVac NV stock (NL0015436031): Delisting amid liquidation process - AD HOC NEWS
5CV.DE Stock Bounces 0.72% on May 12 as CureVac Finds Support - Meyka
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Yahoo Finance
CureVac NV stock (NL0015436031): Is its mRNA platform strong enough to unlock new upside? - AD HOC NEWS
Risk Hedge: Should I hold or sell CureVac NV now2026 Winners & Losers & High Accuracy Investment Signals - baoquankhu1.vn
Signal Recap: Is CureVac NV likely to announce a buybackGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
Profit Recap: Should you avoid CureVac NV stock right now2026 Sentiment & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Aug Ideas: What is the Moat Score of CureVac NV2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Intraday Q1 preview 09 Apr 2026: 5CV.DE stock CureVac N.V. (XETRA): Key catalysts - Meyka
BNTX SEC FilingsBIONTECH 10-K, 10-Q, 8-K Forms - Stock Titan
Audit date correction in BioNTech (NASDAQ: BNTX) 20-F/A filing - Stock Titan
CureVac NV Stock: Biotech Innovator Focused on mRNA Technology and Oncology Pipeline for Long-Term I - AD HOC NEWS
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
Market Wrap: Is CureVac NV likely to announce a buybackWatch List & Capital Efficiency Focused Strategies - baoquankhu1.vn
Magnetar Financial LLC Takes $3.53 Million Position in CureVac N.V. $CVAC - MarketBeat
Earnings Miss: Is CureVac NV stock a buy or sellMarket Growth Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
CureVac (CVAC) Acquisition by BioNTech (BNTX): Your Portfolio Update - Gotrade
CVAC SEC FilingsCurevac B.V. 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
CureVac N.V. (CVAC) Investor Outlook: Analyzing the Biotech’s Future Amid Major Acquisition - DirectorsTalk Interviews
Aug Action: What is CureVac NVs TAM Total Addressable MarketJuly 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
BioNTech sets March 10 webcast for 2025 results update - Stock Titan
CEO Moves: Is CureVac N.V. stock a good dividend stockTreasury Yields & Daily Entry Point Trade Alerts - mfd.ru
CureVac N.V. (CVAC) Stock Analysis: Navigating A Transformational Path In Biotechnology - DirectorsTalk Interviews
CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone - Sahm
CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors - TipRanks
Should you avoid CureVac N.V. stock right nowMarket Movement Recap & Fast Gaining Stock Reports - mfd.ru
New York Life Investment Management LLC Acquires Shares of 258,116 CureVac N.V. $CVAC - MarketBeat
Is CureVac N.V. stock trading near support levelsPortfolio Update Report & Community Driven Trade Alerts - mfd.ru
Is CureVac N.V. stock resilient to inflationMarket Sentiment Report & Technical Entry and Exit Alerts - mfd.ru
Alpine Associates Management Inc. Grows Stock Holdings in CureVac N.V. $CVAC - MarketBeat
CureVac’s Market Exit: A Chapter Closes in the mRNA Race - AD HOC NEWS
CureVac's Public Trading Era Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Delisted Following BioNTech Acquisition Completion () - aktiencheck.de
CureVac’s Market Exit: A New Chapter Begins Under BioNTech - AD HOC NEWS
CureVac's Public Market Journey Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Shares Cease Trading Following BioNTech Acquisition Finalization - AD HOC NEWS
CureVac Aktie: Vorhersehbare Kursbewegungen - Börse Global
CureVac Aktie: Glänzende Zukunftsperspektiven! - Börse Global
CureVac Concludes Nasdaq Listing Following BioNTech Acquisition - AD HOC NEWS
CureVac Shares Cease Trading Following BioNTech Acquisition - AD HOC NEWS
CureVac Aktie: Strategische Prioritäten - Börse Global
Block Trades: How does SIFY score in quality rankingsInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
CureVac N.V. (CVAC): Investor Outlook on the German mRNA Innovator Amidst Acquisition by BioNTech - DirectorsTalk Interviews
Curevac N V (CVAC) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
1.91%
大文字化:
|
ボリューム (24 時間):